UnitedHealth Group Introduces FY25 Guidance, Sees EPS $29.50-$30.00 Vs $29.92 Est.; Revenue $450B-$455B Vs $431.435B Est.
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Check Out What Whales Are Doing With UNH
'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Nasdaq, S&P Ebb Near Record Highs, Dow Slips as JOLTS Report Kicks off Run of Jobs Data
Amedisys Falls as Divestiture Buyer in Sale to UnitedHealth Has Legal Judgement Against It
Screening For Black Friday Bargains In The Stock Market
Sector Update: Health Care Stocks Decline Premarket Tuesday
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Ahead of October JOLTS Report
Concerned about falling behind eli lilly and co, the novo-nordisk a/s india team is reportedly urging an early launch of Wegovy.
①It is reported that novo-nordisk a/s india team recently proposed to advance the market launch time to 2025, which is roughly the same as eli lilly and co's expected time for the launch of its weight loss drug Mounjaro; ②The novo-nordisk a/s india team stated that if Wegovy cannot be launched early in india, the company may lag behind eli lilly and co in this market.
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
Leading And Lagging Sectors For December 3, 2024
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Merck & Co Unusual Options Activity For December 02
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos